Cryoablation of localized prostate cancer. Experience in 48 cases, PSA and biopsy results

Eur Urol. 1998 Sep;34(3):181-7. doi: 10.1159/000019709.

Abstract

Objectives: As the first German center to perform perineal cryoablation of localized prostate cancer, we present our experience in a series of 48 consecutive patients.

Methods: 7 patients staged T1, 21 with T2 disease and 20 patients with T3 tumor were treated. 62.5% of the patients received neoadjuvant hormonal downsizing. Follow-up ranged from 4 to 27 months with a median of 15 +/- 5.7 months.

Results: Positive control biopsies after 6 months were obtained in 0% of T1 tumors, 16.7% of T2 tumors and 26.7% of T3 tumors. Prostate-specific antigen persistence above 1 ng/ml was diagnosed in 14.3, 33.3, and 40%, respectively. Complications were acceptable. 22.9% of the patients had prolonged urinary retention, requiring transurethral resection in 5 patients (10.4%) to relieve obstruction. In 5 cases (10.4%) incontinence was found, in 2 of these patients mild urge incontinence declined over time, in 3 cases moderate to severe stress incontinence developed. Two of these patients were pretreated with radiotherapy. No fistulae were noted.

Conclusions: Cryoablation of the prostate is not a substitution for radical prostatectomy but enables the surgeon to perform a radical curative procedure in patients unfit for other radical forms of treatment or unwilling to undergo these. Long-term follow-up and prospective studies are necessary to define the clinical significance of this procedure.

MeSH terms

  • Aged
  • Androgen Antagonists / therapeutic use
  • Biopsy, Needle*
  • Cryosurgery* / adverse effects
  • Humans
  • Male
  • Middle Aged
  • Neoadjuvant Therapy
  • Postoperative Complications
  • Prostate / pathology*
  • Prostate-Specific Antigen / blood*
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / surgery*

Substances

  • Androgen Antagonists
  • Prostate-Specific Antigen